These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 9608763)
21. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)]. Damier P; Tremblay L; Féger J; Hirsch EC Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093 [TBL] [Abstract][Full Text] [Related]
22. Current controversies: levodopa in the treatment of Parkinson's disease. Sharma JC; Vassallo M; Ross IN Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129 [No Abstract] [Full Text] [Related]
23. Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease. Deogaonkar M; Subramanian T Brain Res Brain Res Rev; 2005 Dec; 50(1):156-68. PubMed ID: 16026845 [TBL] [Abstract][Full Text] [Related]
24. Peak-dose dyskinesia; an acceptable price for mobility in late-stage Parkinson's disease? Wenzelburger R Clin Neurophysiol; 2005 Sep; 116(9):1997-8. PubMed ID: 16055380 [No Abstract] [Full Text] [Related]
33. Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias. Contin M; Martinelli P; Albani F; Scaglione C; Avoni P; Rizzo G; Baruzzi A Clin Neuropharmacol; 2007; 30(2):122-4. PubMed ID: 17414945 [No Abstract] [Full Text] [Related]
34. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients]. Vaamonde J; Ibáñez R; Gudín M; Hernández A Neurologia; 2003 Apr; 18(3):162-5. PubMed ID: 12677484 [TBL] [Abstract][Full Text] [Related]
35. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808 [TBL] [Abstract][Full Text] [Related]
36. Dyskinesia induced by gabapentin in idiopathic Parkinson's disease. Raju PM; Walker RW; Lee MA Mov Disord; 2007 Jan; 22(2):288-9. PubMed ID: 17089397 [No Abstract] [Full Text] [Related]
37. Opioids and motor complications in Parkinson's disease. Samadi P; Bédard PJ; Rouillard C Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075 [TBL] [Abstract][Full Text] [Related]
38. Role of dopamine receptors in neurological drug treatment. Rinne UK Ann Clin Res; 1988; 20(5):334-9. PubMed ID: 3218905 [No Abstract] [Full Text] [Related]
39. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135 [TBL] [Abstract][Full Text] [Related]
40. [Long-term complications of treatment with levodopa]. Castro García A; Sesar Ignacio A Neurologia; 1998; 13 Suppl 1():41-8. PubMed ID: 9859685 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]